| Mouse models for atherosclerosis and pharmaceutical modifiers S Zadelaar, R Kleemann, L Verschuren, J de Vries-Van der Weij, ... Arteriosclerosis, thrombosis, and vascular biology 27 (8), 1706-1721, 2007 | 702 | 2007 |
| Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism AE van Herwaarden, E Wagenaar, CMM van der Kruijssen, ... The Journal of clinical investigation 117 (11), 3583-3592, 2007 | 260 | 2007 |
| Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin [S] S Kühnast, JWA van der Hoorn, EJ Pieterman, AM van den Hoek, ... Journal of lipid research 55 (10), 2103-2112, 2014 | 241 | 2014 |
| The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden. CETP mice C Landlinger, MG Pouwer, C Juno, JWA van der Hoorn, EJ Pieterman, ... European heart journal 38 (32), 2499-2507, 2017 | 228 | 2017 |
| Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice JWA van der Hoorn, W de Haan, JFP Berbée, LM Havekes, JW Jukema, ... Arteriosclerosis, thrombosis, and vascular biology 28 (11), 2016-2022, 2008 | 221 | 2008 |
| Perfluoroalkyl sulfonates cause alkyl chain length–dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE* 3-Leiden CETP mice S Bijland, PCN Rensen, EJ Pieterman, ACE Maas, JW van der Hoorn, ... Toxicological Sciences 123 (1), 290-303, 2011 | 154 | 2011 |
| Remote ischaemic preconditioning by brief hind limb ischaemia protects against renal ischaemia-reperfusion injury: the role of adenosine KE Wever, MC Warlé, FA Wagener, JW van der Hoorn, R Masereeuw, ... Nephrology Dialysis Transplantation 26 (10), 3108-3117, 2011 | 126 | 2011 |
| Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin W de Haan, J de Vries-van der Weij, JWA van der Hoorn, T Gautier, ... Circulation 117 (19), 2515-2522, 2008 | 113 | 2008 |
| Autoantibodies against mannose-binding lectin in systemic lupus erythematosus MA Seelen, LA Trouw, JWA van der Hoorn, FC Fallaux-Van Den Houten, ... Clinical & Experimental Immunology 134 (2), 335-343, 2003 | 100 | 2003 |
| Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin S Kühnast, SJL van der Tuin, JWA van der Hoorn, JB van Klinken, B Simic, ... European heart journal 36 (1), 39-50, 2015 | 92 | 2015 |
| Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy JW Jukema, JWA van der Hoorn Expert opinion on pharmacotherapy 5 (2), 459-468, 2004 | 92 | 2004 |
| PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE [S] B Ason, JWA van der Hoorn, J Chan, E Lee, EJ Pieterman, KK Nguyen, ... Journal of lipid research 55 (11), 2370-2379, 2014 | 78 | 2014 |
| APOE* 3Leiden. CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome AM van den Hoek, JWA van der Hoorn, AC Maas, RM van den Hoogen, ... Diabetes, Obesity and Metabolism 16 (6), 537-544, 2014 | 68 | 2014 |
| Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE* 3-Leiden. CETP mice JFP Berbée, MC Wong, Y Wang, JWA van der Hoorn, PPSJ Khedoe, ... The Journal of Nutritional Biochemistry 24 (8), 1423-1430, 2013 | 63 | 2013 |
| Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta … S Kühnast, M Fiocco, JWA van der Hoorn, HMG Princen, JW Jukema European journal of pharmacology 763, 48-63, 2015 | 58 | 2015 |
| Niacin reduces atherosclerosis development in APOE* 3Leiden. CETP mice mainly by reducing nonHDL-cholesterol S Kühnast, MC Louwe, MM Heemskerk, EJ Pieterman, JB van Klinken, ... PloS one 8 (6), e66467, 2013 | 57 | 2013 |
| Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein J de Vries-van der Weij, W de Haan, L Hu, M Kuif, HLDW Oei, ... Endocrinology 150 (5), 2368-2375, 2009 | 54 | 2009 |
| Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE* 3Leiden mice without affecting liver or plasma triglyceride levels JWA van der Hoorn, D Lindén, U Lindahl, MEA Bekkers, M Voskuilen, ... British journal of pharmacology 162 (7), 1553-1563, 2011 | 49 | 2011 |
| Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE* 3-Leiden. CETP mice S Bijland, EJ Pieterman, ACE Maas, JWA van der Hoorn, MJ van Erk, ... Journal of biological chemistry 285 (33), 25168-25175, 2010 | 47 | 2010 |
| Gender-dependent effects of high-fat lard diet on cardiac function in C57Bl/6J mice MC Louwe, JWA van der Hoorn, SAA van den Berg, JW Jukema, ... Applied physiology, nutrition, and metabolism 37 (2), 214-224, 2012 | 44 | 2012 |
